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Abstract: The view that B lymphocytes are pathogenic in diverse pathological settings is 
  supported by the efficacy of B-cell-ablative therapy in lymphoproliferative disorders, autoimmune 
diseases and graft rejection. Anti-B-cell antibodies (Abs) directed against CD20 have therefore 
been generated, and of these, rituximab was the first anti-CD20 monoclonal Ab (mAb) to be 
applied. Rituximab-mediated apoptosis, complement-dependent cytotoxicity and Ab-dependent 
cellular cytotoxicity differ from one disease to another, and, for the same disease, from one 
patient to another. This knowledge has prompted the development of new anti-CD20 mAbs in the 
hope of improving B-cell depletion. The inclusion of CD20/anti-CD20 complexes in large lipid 
rafts (LRs) enhances the results of some, but not all, anti-CD20 mAbs, and it may be possible to 
include smaller LRs. Lipid contents of membrane may be abnormal in malignant B-cells, and 
could explain resistance to treatment. The function of these mAbs and the importance of LRs 
warrant further investigation. A detailed understanding of them will increase results for B-cell 
depletion in lymphoproliferative diseases.
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Introduction
B lymphocytes perform a variety of functions in the immune system. For example, they 
play a part in eradicating bacteria or viruses, and promote all antitumoral responses.1 
They may, however, run the risk of upregulating immune reactions. In autoimmunity, 
there is sufficient evidence to justify investigating B lymphocytes not only as antibody 
(Ab) producing cells at the end of the pathological sequence, but also in the early stages 
of pathophysiology.2 These negative effects of B lymphocytes may be seen in graft 
rejection, which is associated with the production of Abs,3 and in graft versus host 
(GVH) disease following allogeneic hematopoietic stem cell transplantation.4 Moreover, 
there is anarchic proliferation of B lymphocytes in lymphoproliferative syndromes 
such as lymphomas5 and chronic lymphocytic leukemia (CLL).6 Not surprisingly, 
B-cell-ablative therapies have been proposed for B-cell non-Hodgkin’s lymphoma 
(NHL), representing a major advance in its treatment. One of these therapies involves 
anti-CD20 monoclonal Abs (mAbs), which are directed against the CD20-expressing 
members of the B-cell lineage, from late pre-B-cells through mature B-cells. Rituximab 
(RTX) was the first mouse–human chimeric mAb to be approved by the Food and Drug 
Administration (FDA) for the treatment of relapsed, or refractory, low-grade NHL.7 
RTX is now used in other malignant proliferations,8 and is approved by the FDA for 
the treatment of autoimmune diseases (AIDS)9  and the prevention of graft rejection.10 
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been treated with RTX, and the improved patient-reported 
outcomes and cost-effectiveness have led to the production 
of other anti-B-cell agents. As a consequence, humanized 
anti-CD20 Abs are currently being developed.11–14
The effectiveness of anti-CD20 mAbs for a given disease 
is variable, as reported in patients with NHL or CLL.15–18 Fur-
thermore, their self-efficacy differs from one B-cell disease to 
another. In fact, compared to observations with lymphoma, 
RTX has been shown to be weak when used as a single agent 
in CLL.19,20 These data therefore suggest that the results could 
be affected by factors in B lymphocytes themselves. The 
present review endeavors to chronicle therapeutic indica-
tions of anti-CD20 mAbs in these malignancies, to analyze 
the mechanisms of their action and to distinguish extrinsic 
or intrinsic factors, particularly lipid rafts (LRs) that could 
possibly be modulating their activities.
Diseases treated with rituximab
Malignant B-cell diseases
Non-Hodgkin B-cell lymphoma
Many clinical trials have been conducted as induction 
therapy for patients recently diagnosed with follicular 
lymphoma or who have suffered a relapse when RTX was 
used on its own, in combination with chemotherapy, or with 
other types of Abs. Generally speaking, these mAbs, or the 
related combination of drugs, prolong survival compared to 
chemotherapy alone.21 Other trials have tested the efficacy 
of RTX in Waldenström’s macroglobulinemia (WM) and 
multiple myeloma.22 In fact, Demopoulos et al have claimed 
that combining RTX with other drugs is the most commonly 
used primary treatment for WM.23 Diffuse large B-cell 
lymphoma (DLBL), which accounts for approximately 
40% of NHLs in adults, is a type of aggressive lymphoma 
with a diffuse growth pattern and a high-intermediate 
proliferation index. Combining RTX with chemotherapy 
represents a breakthrough in the treatment of malignancies, 
and could become the new standard therapy in elderly and 
young low-risk patients.24 In addition, treatment of Burkitt’s 
lymphoma, marginal lymphoma and Hodgkin lymphoma 
with RTX is currently being investigated (Table 1).
Its success notwithstanding, around 50% of NHL patients 
resisted treatment with RTX in that they did not respond to it, 
or they suffered an early relapse of the original disease.
Leukemias
These disorders are, in fact, bone marrow (BM) diseases. As 
in previous papers, we show the results of treating CLL and 
acute lymphocytic leukemia (ALL) with RTX. Many clini-
cal trials have been conducted on CLL,25 but the efficacy of 
RTX was weak compared to its effects with lymphoma. One 
explanation is that RTX reduces the membrane level of CD20 
on CLL B-cells. This is reflected in the fact that fractionation 
of RTX into several low doses perpetuates the expression 
of CD20, and thereby prolongs the activity of the mAb.26,27 
Finally, the results of combining RTX with chemotherapy in 
the treatment of ALL appear to be encouraging, with accept-
able levels of toxicity (Table 1).28
Autoimmune diseases
Autoimmune diseases where RTX is known  
to be efficient
A pilot study, RTX in AID, was set up in 2000 for the 
treatment of immune thrombocytopenic purpura. Objective 
clinical responses were observed in 30% of cases29 and 
the beneficial effect of RTX was confirmed in others.30,31 
Furthermore, the use of RTX with methotrexate has been 
approved by the FDA for the treatment of rheumatoid 
arthritis (RA), as it relieves symptoms in adult patients 
with moderate to severe active RA where treatment with 
one or more   anti-TNF drugs has failed. RTX was also 
tested in Sjögren’s syndrome with interesting results,32 
and in systemic lupus erythematosus (SLE) where reduced 
activity of the disease and a clinical response of 86% were 
reported in one series of patients.33,34 However, certain SLE 
AID: iTP, idiopathic thrombocytopenic purpura; RA, Rheumatiod, Arthritis; SS, Sjogren’s syndrome; SLe, Systemic lupuserythematosus; MS, Multiple sclerosis; 
ANCA, Antineutrophil cytoplasmic antibodies; DM, dermatomyositis; PM, polymyositis; GvHD, graft versus-host disease.
Lymphomas: DLBL, diffuse large B cell lymphoma; MALT, Mucosa-associated lymphoid tissue lymphoma; MCL, Mantle cell lymphoama; FL, follicular lymphoma; 
HL, Hodgkin lymphoma.
Leukemia: ALL, actue lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HCL, Hairy cell leukemia.
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patients show only partial or brief B-cell depletion, while 
the clinical benefit, if any, is modest.35 This failure suggests 
that SLE results from altered B-cell sensitivity, or possibly 
a complement (C) dysfunction.36 Multiple sclerosis and 
antineutrophil cytoplasmic Abs-associated vasculitides have 
been studied for RTX efficiency, but controlled clinical trials 
have not yet been reported (Table 1).37,38
AiD suspected of answering Abs
Finally, anecdotal cases of anti-CD20 B-cell depletion 
have been reported in autoimmune-hemolytic anemia, 
cryoglobulinemia, acquired factor VIII-inhibitor disease, 
glomerulonephritis, pemphigus vulgaris, systemic sclero-
derma, polymyositis and dermatomyositis.39–43 An ongoing 
phase-I trial is even treating inactive psoriasis with RTX. 
Intriguingly, however, a handful of case reports suggest 
that this B-cell ablative therapy may actually induce 
psoriasis.44,45
Graft rejection and graft versus 
host disease
The pathogenic role of B lymphocytes was highlighted in 
renal, cardiac, liver or pancreas transplantation, justifying 
B-cell depletion with RTX.46–48 Allogeneic hematopoietic 
stem cell transplantation may induce acute or chronic 
destruction of the host by the donor’s immune system. Whilst 
pathogenic mechanisms involved in these phenomena are not 
clearly understood, RTX therapy may be effective for some 
patients (Table 1).49
Action mechanisms of rituximab
Complement-dependent cytotoxicity
C may be utilized by RTX, and C-dependent cytotoxicity 
(CDC) seems to be pivotal in the efficiency of RTX.50 In fact, 
after RTX treatment, C deficiency or consumption is strik-
ing in patients with CLL,51–53 with the over expression of C 
inhibitors CD55 and CD59.18,22 Klepfish et al tried to enhance 
the activity of RTX in CLL by adding fresh frozen plasma in 
an attempt to correct the C imbalance.52 Moreover, resistance 
to RTX therapy in NHL was ascribed to CDC inefficiency, as 
polymorphisms in the C1qA gene were affecting its clinical 
response and the duration of the response.54,55 Following treat-
ment with RTX, the CD20 molecules are clustered in the LRs, 
concentrating IgG Fc regions locally and therefore inducing 
fixation of C1q. The C molecule, C3, has been shown to vary 
in affinity for LRs by   supplementing cholesterol in cellular 
membrane and by virtue of the   hypersensitivity of CD55 to 
phospholipases.56,57
Antibody-dependent cell-mediated 
cytotoxicity
ADCC occurs when B-cells are killed by monocytes, mac-
rophages, natural killer (NK) cells and neutrophils following 
the binding of RTX to the Fc region. Among the Fc-gamma 
receptors (Fcγ), FcγRII was shown to inhibit ADCC, whereas 
FCγRIIIA behaved as an activator. However, a polymorphism 
of this latter receptor was also found to modulate ADCC. On 
the other hand, there is a dimorphism on residue 176 which 
can either be valine, with a high binding of IgG1, or pheny-
lalanine with a low binding.58 Cartron et al confirmed that a 
homozygous valine 158 polymorphism of FcγRIIIA leads to 
higher response rates and molecular complete remission rates 
in NHL patients after RTX treatment.59 However, in CLL, 
ADCC was not influenced by the FcγR genotype expressed 
by autologous NK cells.17
Apoptosis
RTX-induced apoptosis requires translocation of CD20 
into the LRs.60 This segregation increases cytosolic Ca2+ 
levels through association between CD20 and the B-cell 
receptor (BCR).61 Interaction between CD20 and raft mem-
brane protein permits activation of components such as 
the phosphotyrosine kinases Lyn, Fyn, and Lck, as well as 
p75/80 (Cbp/PAG). This appears to be necessary for RTX,57 
downstream signals mediated by the mitogen-activated pro-
tein kinase (MAPK) p38, cleavage of caspase-3, inhibition 
of Bcl-2, DNA fragmentation and, ultimately, apoptosis.62 
Growth inhibition of NHL cell lines by RTX may be caused 
by externalization, location in LRs with CD20 and acid 
sphingomyelinase production through ceramide synthesis, 
which also activates MAPK. However, Chan et al demon-
strated that, in several cell lines at least, redistribution of 
CD20 was not crucial.63
Why is the efficacy of RTX variable?
is the quantity relevant?
Number of lymphocytes
The efficacy of anti-CD20 mAb depends of the number of 
tumor cells. In fact, when the tumor burden is high, the vari-
ous effector mechanisms engaged by RTX are saturated.19 
Kennedy et al confirmed this observation through an analysis 
of elevated B CLL cell concentration binding by RTX, which 
led to complete consumption of C lytic activity and depletion 
of several C components.53 Their replacement with purified 
C proteins is sufficient to restore the cytotoxic activity of 
RTX. In aggressive DLBL, association between RTX and OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
102
Hammadi et al
chemotherapy improves the rate and increases the duration 
of the response.64
Other variables for a fixed number of B-cells
Number of CD20 molecules
CD20, a nonglycosylated phosphoprotein, is expressed in 
large quantities on the surface of almost all normal and 
malignant B-cells, up to 250,000 molecules per cell. How-
ever, resistance to RTX was identified in certain diseases, and 
especially in CLL. Mankai et al and others have established 
that this is related to a lower density of CD20 on B-cells in 
CLL compared to B-cells from other lymphomas,65 associ-
ated with a down-regulation of the purine-rich box-1 (PU.1) 
transcription factor, so that transfection of B-cells with its 
cDNA restores RTX-induced lysis. Similarly, stimulation 
of B-cells with CpG increases the expression of CD20 and 
ameliorates the CDC by RTX.66 The same results have been 
observed in lymphoma,20 but Weitzman et al claim that there 
was no correlation between ADCC and CD20 density.17
Location of the B-cells
After an infusion of RTX, circulating B-cells are rapidly 
removed. In contrast, germinal-center and marginal-zone 
B-cells resist this destruction.67 This phenomenon seems 
to be linked to factors such as BAFF (B-cell-activating 
factor) from the microenvironment, integrins and the lack 
of vascularization, rather than to poor tissue penetration by 
RTX. This factor is more decisive for RTX susceptibility 
than for the density of Fcγ receptors on the membrane of 
all effectors.68 We can note that the level of BAFF in sera 
from patients with lymphoma may be a useful indicator in 
predicting the efficacy of treatment with RTX and chemo-
therapy.69 Furthermore, baseline serum levels of BAFF are 
inversely correlated with the induration of B-cell depletion 
after RTX treatment in primary Sjögren’s syndrome.70 These 
findings provide new options for treating AID and hemato-
logical malignancies.
Quality implication
Lipid rafts
LRs have been described as stable structures, 100–500 nm 
in diameter, which resist extraction by nonionic   detergents 
at low temperature due to their high cholesterol and 
  glycosphingolipid content.71 This definition is misleading and 
may not apply to the composition of LRs in vivo. In fact, this 
structure is no longer accepted, and LRs are considered to be 
very heterogeneous, differing in the temporal stability of the 
composition of their lipids and proteins such as Src kinases. 
The generally accepted definition of LRs was agreed at the 
2006 Keystone symposium on LRs and cell function: “Lipid 
rafts are small (10–200 nm), heterogeneous, highly dynamic, 
sterol- and sphingolipid-enriched domains that compart-
mentalize cellular processes”. The largest components of 
LRs are glycosphingolipids such as ganglioside M1 (GM1), 
sphingomyelin (SM), cholesterol and phosphatidyl serine, 
the last three in approximately 50% greater quantities than 
in plasma membranes (Figure 1). “Small rafts can sometimes 
be stabilized to form larger platforms through protein–protein 
and protein–lipid interactions”.72–74 When plasma membrane 
lipids and protein are clustered in the LRs, they can mediate 
transduction pathways which favor cellular adhesion, trans-
membrane signaling, virus budding, control of ionic pumps 
and channels, and mediation of vesicle fusion.75,65
Proteins connected to LRs have been described as insol-
uble in the nonionic detergent Triton X-100 at low tempera-
ture, in contrast to the other membrane lipids.70 This means 
we should be careful when investigating proteins linked to 
rafts, as analyses of fluorescence microscopy or fluorescence 
resonance energy transfer confirm these data.77 Many of these 
signaling proteins either reside in, or are transferred into, the 
LRs during signal transmission. Their fine-tuned regulation is 
probably influenced by nanoscale membrane microdomains, 
which are defined as dynamic and which apportion them to 
the membrane.78 These include CD20,79 BCR,77 Fas, HLA II,80 
TNF receptor, CD40,81 phosphatidyl inositol 3-kinase and 
several protein kinase C isoforms. Cbp/PAG, a ubiquitous, 
highly tyrosine-phosphorylated adaptor protein, only occurs 
in LRs, and plays an important part in the recruitment of Lyn, 
Fyn and Lck kinases into these LRs (Figure 1).82
Glycosphingolipids are involved in cell proliferation 
and differentiation. Glycosyl ceramides are the most widely 
distributed glycosphingolipids in cells, and act as precursors 
for the biosynthesis of many glycosphingolipids. GM1, 
widely used as a marker for LRs, is a sialoglycosphingolipid 
composed of a ceramide hydrophobic portion and a oligosac-
charide sequence (Figure 2). It is integrated into the external 
leaf of the plasma membrane, and is at the forefront of the 
interaction of cells with their environment. For example, 
GM1 is known as a receptor for toxins and viral particles.83,84 
Furthermore, close interaction between SM and cholesterol 
is necessary for LR formation, and sphingomyelinase can 
transform small LRs into large, ceramide-enriched ones. 
In addition, glycosphingolipids can be metabolized into 
lysosphingolipids and sphingoid bases. This function as a 
metabolite acts as second messenger in signal transduction 
pathways of growth and apoptosis.85,86OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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variation in their composition
A recent study analyzing LR constitution in mantle cell 
lymphoma has revealed a downregulation of key LR proteins 
such as raftlin and Cbp/PAG.87 These are involved in B-cell 
transduction and in the pathology of lymphoma. Moreover, 
the presence of Cbp/PAG in the LRs is necessary for RTX 
to effect transmembrane signaling.57 The resistance of tumor 
B-cells to RTX may be explained by a deficiency in Cbp/
PAG. If we take this a step further, changes in the expression 
of a number of glycosphingolipids on the cell surface have 
been correlated with typical cancer phenotype and tumor 
progression. In this respect, GM1 expression differs between 
lymphoma subtypes, even within one lymphoma subgroup. 
A recent study has demonstrated a correlation between the 
expression of GM1 and response to RTX in NHL and CLL.88 
In this latter leukemia, B lymphocyte membrane appears 
with increased fluidity, and produces lipid dynamics and 
lipid-protein interactions.89,90 Furthermore, glucosylceramide, 
lactosylceramide and SM improve activity of P-glycoprotein, 
a membrane efflux transporter, which frequently underlies 
cancer cell and bacterial resistance.91 There are excessive 
quantities of B lymphocytes in CLL patients.92,93 In addition, 
glucosylceramide synthase inhibitors stimulate CLL cells to 
react to conventional cytotoxic and cytostatic drugs used in 
treatment.94
Finally, the disialoganglioside (GD3), a ganglioside 
weakly expressed in most normal tissues, is over-expressed 
during development and in pathological conditions such 
as cancer. It is responsible for a variety of events such as 
proliferation, differentiation and apoptosis.95 However, the 
relationship between ganglioside GD3 and CLL is not fully 
understood. It should be noted that alterations in the LR 
  localization of certain signaling molecules contribute to 
the acuteness of B-cell-dependent autoimmune disease 
in some cases. On the other hand, the majority of SLE 
patients exhibited a low level of Lyn expression as well as 
a diminished association with LRs, due to an increase in 
ubiquitination through translocation of c-Cbl into LRs.96,97 
This is associated with the abnormal expression of CD45, 
a membrane protein, tyrosine phosphatase, which controls 
Lyn expression by modulating its phosphorylation.98 Lyn 
serves as a negative regulator for B-cell signaling, and 
reduced negative   signaling in LRs hyperactivates B-cells, 
leading to uncontrolled production of IL-10 and auto-Abs. 
The development of SLE induced by abnormalities in the 
sub-cellular localization of the BCR signaling pathway was 
confirmed by the discovery of a single polymorphism in the 
FcγRIIB gene.99 This mutation excludes FcγRIIB from the 
LRs and impedes its inhibitory effects on BCR signals.100
Efficacy of other anti-CD20 mAbs
There is a clear need to develop new agents in order to improve 
the efficacy of B-cell depletion. In fact, there are many forms 
of resistance to RTX in autoimmune conditions and B-cell 
malignancies. On the other hand, other anti-CD20 mAbs have 
been, or are currently being developed (Table 2).
CDC-improving anti-CD20 mAbs
Ofatumumab (2F2, HuMax-CD20, Genmab/GSK) is a fully-
humanized, anti-CD20 mAb which binds to a portion closer 
to the B-cell membrane, and which is composed of the 74–80 
amino acids in its small extracellular loop (Figure 3). Pre-
clinical studies have thus far established that Ofatumumab 
has a slower rate of dissociation from CD20 than RTX 
and greater CDC power. Lysis of refractory RTX-resistant 
B-cells is also effected through this mAb,50 with sustained 
success.14 Moreover, infusion reactions which appear after 
use of Ofatumumab are similar to those which appear with 
RTX, and it is more effective in CLL patients.101
Veltuzumab (IMMU-106, hA20, Nycomed/Immuno-
medics) is a humanized mAb with complementarity-deter-
mining regions (CDRs) identical to RTX, except at position 
101 in the CDR3 of the variable heavy chain (VH) in aspartic 
acid substitutes for asparagines, and in framework regions 
of Epratuzumab, another humanized anti-CD22 Ab. This 
difference induces ADCC identical to that of RTX in CLL.17 
There is a reduced off-rate102 and greater efficacy in lysing 
tumor cells in vitro by CDC, and also in vivo with a phase I/
II for recurrent/refractory NHL.13
ADCC-increasing anti CD20 mAbs
Ocrelizumab (2H7) is a 90%–95% humanized mAb 
  (Genentech/Roche/Biogen-Idec), and binds to an epitope which 
is different to that of RTX but which overlaps with it, and which 
is in the extracellular domain of CD20.103 Because C activation 
leads to side effects associated with RTX, a modification of its 
Fc portion is necessary. Its gives mAb a reduced CDC12 and 
increases its tolerability in autoimmune diseases. On the other 
hand, ADCC is higher than with RTX, due to amplified binding 
affinity for the low-affinity variants of FcγRIIIa.
Modifications to anti-CD20 Ab glycosylation, aimed at 
increasing ADCC, have generated three anti-CD20 mAbs. 
GA-101 is a humanized third-generation and glyco-  engineered 
version of anti-CD20 mAb (Glycart   Biotechnology AG, Genen-
tech Inc, F Hoffmann-LaRoche Ltd, Biogen Idec Inc and Chugai 
Pharmaceutical Co Ltd) which produces greater ADCC, supe-
rior direct cell death and greater efficacy in depleting B-cells 
than RTX in the potential treatment of NHL or CLL.104 EMAB-
6, with a low fucose content, triggers similar apoptosis and OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Figure 3 Fixation of ofatumumab on CD20 small extracellular loop.
Table 2 Major characteristics of anti-CD20 antibodies compared to activity of rituximab
++ +++ +++ − humanized IgG1 GA-101 (Glycart Biotechnology 
AG, Genentech/Roche) 
++ +/− − mouse IgG2a Tositumomab (B1- 
GlaxoSmithKline)
++ ++ +
++ 
(FcγRIIIa)
+ fully human Experimental mAb 1,5,3 
(Amgen/Astrazeneca)
++ ++ humanized BLX-301 (Biolex/Argen)
+ + ++ + chimeric with low 
fucose content
EMAB-6 (LFB)
+ ++ +/− humanized IgG1 Ocrelizumab (2H7- 
Genentech/Roche/Biogen-Idec)
++ ++ +++ humanized IgG1 Veltuzumab (IMMU-106, hA20-  
Nycomed/Immunomedics)
+ ++ +++ fully human IgG1  Ofatumumab (2F2- 
Genmab/GSK)
Very efficient in 
B cells expressiong 
low CD20 levels 
B cell 
depletion 
Apoptosis ADCC CDC
Mechanisms of action Antibody 
Specificity
Abbreviations: CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cellular cytotoxicity. OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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CDC to that observed for RTX, but promotes ADCC in CLL. 
The different levels of efficacy are more pronounced with low 
doses and when target cells express fewer CD20 molecules.105 
BLX-301 (Biolex/Aragen) is a humanized anti-CD20 mAb with 
an optimized glycosylation structure, enhanced ADCC, potent 
B-cell depletion, and potentially low side effects. BLX-301 is 
being developed for treatment of NHL.
Finally, the objective of protein engineering is to manufacture 
an anti-CD20 Ab with greater potency and efficacy in all patients. 
Thus, vaccines are being developed with CD20 mimotope pep-
tides106 and AME-133v (Lilly), which improve the binding of anti-
CD20 mAb to the Fc receptor on their immune effectorcells.
Anti-CD20 mAbs which increase 
programmed cell death
Zevalin, an anti-CD20 mAb linked to Yttrium-90 (IDE-
CY2B8, Ibritumomab Bayer Biogen Idec) and Bexxar 
(Tositumomab, B1 coupled to iodine I131-GlaxoSmithKline) 
were approved by the FDA in 2002 and 2003 respectively for 
treatment of NHL and for trials in other malignant diseases 
such as CLL.107 It is worthy of note that unradiolabeled tosi-
tumomab was described as inducing stronger apoptosis and 
ADCC than RTX.108
The Amgen/AstraZeneca mAb 1.5.3 better enhances 
proapoptotic activity in vitro than RTX, and mediates both 
CDC and ADCC, with superior ADCC when NK donor cells 
present an FcγIIIa F/F allotype. In a primate pharmacody-
namic model, this promotes higher B-cell depletion in lymph 
node organs and BM.109
The genetically-engineered tetravalent Ab (TetraMcAb), 
derived from the anti-CD20 mAb RTX and ofatumumab, 
exhibits more potent antiproliferative and apoptosis activities 
than ofatumumab or RTX.110 Hex-hA20, which comprises six 
Fabs with one Fc, translocates CD20 in LRs, affects ADCC 
but not CDC, and inhibits proliferation of NHL cell lines in 
vitro at low level concentration without requiring antibody 
cross-linking.111
Conclusion
The efficacy of anti-CD20 mAbs seems to depend, at least 
in part, on their ability to translocate CD20 molecules into 
LRs. Apoptosis is higher in those which cannot do so, where 
mAbs which can do so are characterized by CDC. ADCC 
is the same in both types. New anti-CD20 mAbs have been 
developed based on this classification. Mechanisms dif-
fer according to the type of B-cell-disease and the type of 
patient. These mAbs will be able to be used to best effect 
when their precise roles are known, and when   B-cell-disorder 
  physiopathology is better understood. For the time being, 
performance could be improved by increasing doses of 
mAbs, changing the type of mAb for each disease, asso-
ciating different drugs simultaneously or successively, and 
modifying the LRs.
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